Skip to main content
ZVRA logo

Zevra Therapeutics, Inc.

ZVRANASDAQHealthcareBiotechnology

$9.53Today:- (-)1Y −3.28%

As of Oct 26, 2026 close

Market cap
$584.54M
P/E (TTM)
10.03
Forward P/E
5.96
Dividend yield
-
52-week range
$8.01$15.04
Volume (live)
-
Avg. volume (3M)
877.51K

Zevra Therapeutics (ZVRA) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Zevra Therapeutics had a P/E ratio of 6.50, return on equity of 85.7% (up from -207.8%), debt-to-equity of 0.41 (down from 1.52) and a current ratio of 5.68 (up from 2.52). A current ratio of 5.68 means current assets exceed current liabilities.

Zevra Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income StatementBalance SheetCash FlowRatios
Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio6.50-----
Forward P/E19.14102.50102.50102.5024.172.95
P/S Ratio4.7418.859.8915.5910.743.64
P/B Ratio3.2611.224.392.112.42-0.73
Price/Tangible Book3.51--2.112.42-
Price/FCF----29.76-
Price/OCF----29.47-
Enterprise Value Ratios
EV/Revenue3.4517.618.499.526.218.43
EV/EBITDA----22.27-
EV/EBIT----23.01-
EV/FCF----17.20-
Profitability & Returns
Return on Equity (ROE)85.66%-207.84%-67.23%-26.48%-28.18%-
Return on Assets (ROA)-1.14%-31.03%-21.55%-12.54%6.70%-27.52%
Return on Invested Capital (ROIC)-14.18%-254.55%-223.98%-218.60%77.08%-
Return on Capital Employed (ROCE)-1.70%-60.40%-50.30%-24.10%6.00%-130.20%
Leverage & Solvency Ratios
Debt/Equity0.411.520.710.190.01-1.06
Debt/EBITDA92.54---0.18-
Debt/FCF----0.16-
Liquidity Ratios
Current Ratio5.682.521.187.7227.201.11
Quick Ratio5.462.351.167.5826.920.90
Efficiency Ratios
Asset Turnover0.460.140.190.080.401.22
Inventory Turnover8.88-----
Yield & Distribution Ratios
Earnings Yield16.50%-23.70%-16.95%-16.90%-2.78%-26.40%
FCF Yield-0.48%-15.65%-12.45%-11.88%3.36%-4.08%
Buyback Yield-23.81%-30.46%-2.79%-15.87%-647.71%-114.79%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Zevra Therapeutics Financial Ratios

What is Zevra Therapeutics's P/E ratio?

Zevra Therapeutics's P/E ratio was 6.50 for fiscal 2025 (period ended Dec 31, 2025).

What is Zevra Therapeutics's return on equity?

Zevra Therapeutics's return on equity (ROE) was 85.7% for fiscal 2025 (period ended Dec 31, 2025). It was -207.8% a year earlier.

What is Zevra Therapeutics's debt-to-equity ratio?

Zevra Therapeutics's debt-to-equity ratio was 0.41 for fiscal 2025 (period ended Dec 31, 2025). It was 1.52 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition